These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 9513221

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
    Lallemand F, Adda N, Schneider V, Jacomet C, Salhi Y, Rozenbaum W.
    Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M, Salzberger B, Stiepel A, Hoetelmans R, Diehl V, Fätkenheuer G.
    Eur J Med Res; 1999 Feb 25; 4(2):54-8. PubMed ID: 10066640
    [Abstract] [Full Text] [Related]

  • 6. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr 25; 8(40):55-60. PubMed ID: 10848067
    [Abstract] [Full Text] [Related]

  • 7. Development of HIV protease inhibitors: a survey.
    Ren S, Lien EJ.
    Prog Drug Res; 1998 Apr 25; 51():1-31. PubMed ID: 9949858
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.
    Hugen PW, Verweij-van Wissen CP, Burger DM, Wuis EW, Koopmans PP, Hekster YA.
    J Chromatogr B Biomed Sci Appl; 1999 Apr 30; 727(1-2):139-49. PubMed ID: 10360433
    [Abstract] [Full Text] [Related]

  • 12. Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
    Mascolini M.
    J Int Assoc Physicians AIDS Care; 1997 Jun 30; 3(6):17-21. PubMed ID: 11364427
    [Abstract] [Full Text] [Related]

  • 13. [HIV protease inhibitors].
    Rubio R, Romeu J, Viciana P, Redondo C.
    Enferm Infecc Microbiol Clin; 1996 Oct 30; 14 Suppl 1():10-4. PubMed ID: 9053020
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Drugs for HIV infection.
    Med Lett Drugs Ther; 1997 Dec 12; 39(1015):111-6. PubMed ID: 9402928
    [No Abstract] [Full Text] [Related]

  • 16. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
    Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH.
    Pharm World Sci; 1997 Aug 12; 19(4):159-75. PubMed ID: 9297727
    [Abstract] [Full Text] [Related]

  • 17. AmFAR extols FDA on rapid approval of two protease inhibitors.
    AIDS Patient Care STDS; 1996 Jun 12; 10(3):193-4. PubMed ID: 11361645
    [No Abstract] [Full Text] [Related]

  • 18. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
    Pharm Unserer Zeit; 1997 Dec 12; 26(6):317. PubMed ID: 9513575
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US, Fox Z, Pedersen C, Cahn P, Gerstoft J, Clumeck N, Losso M, Peters B, Obel N, Castagna A, Dragsted UB, Lundgren JD, MaxCmin1 and 2 trial groups.
    Basic Clin Pharmacol Toxicol; 2007 Nov 12; 101(5):339-44. PubMed ID: 17910618
    [Abstract] [Full Text] [Related]

  • 20. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
    Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA.
    J Infect Dis; 2000 Sep 12; 182(3):758-65. PubMed ID: 10950769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.